Treatment is diagnosis-specific. Hip OA, GTPS, and inflammatory arthritis are the three most common primary care conditions. Address all modifiable factors simultaneously.
① Hip Osteoarthritis (NICE NG226)
Step 1Education + exercise (mandatory first-line): Exercise and weight management are core treatments (NICE NG226) — tailor to preference, function and comorbidity: aerobic exercise (walking, swimming, cycling, aquatic exercise) + hip-specific strengthening. Advise that exercise does not accelerate OA. Provide a Versus Arthritis OA patient information leaflet
Step 2Analgesia — topical then oral: Consider a topical NSAID (NICE NG226 — joints other than the knee); check preparation and frequency against the current product SPC and local formulary, and explain it may have limited value for deep hip joint pain. Paracetamol: NICE NG226 advises against routine use — only infrequently, for short-term relief, when other drug options are contraindicated, not tolerated or ineffective. Avoid strong opioids (no long-term evidence, significant harm — NICE NG226)
Step 3Oral NSAIDs: Consider if topical treatment is ineffective or unsuitable — choose per local formulary, with PPI gastroprotection (NICE NG226); assess overall GI risk rather than applying a fixed age rule. Lowest effective dose, shortest duration. Check eGFR + BP + CVD risk before starting. Avoid in eGFR <30, heart failure, or uncontrolled hypertension
Step 4Intra-articular corticosteroid injection: Consider for short-term relief or to facilitate exercise (NICE NG226). Performed by a suitably trained clinician, often image-guided because the joint is deep. Frequency per local procedural policy. Do not use hyaluronan injections
Step 5Total hip replacement referral: symptoms substantially affecting quality of life with non-surgical management ineffective or unsuitable (NICE NG226 — a score such as the Oxford Hip Score describes severity but is not a referral threshold), no fixed period of failed treatment is required before referral. Discuss: implant lifespan, risks (VTE, infection, dislocation) and realistic recovery
NICE NG226 explicitly states: Do not routinely offer opioids, particularly strong opioids. Do not routinely offer paracetamol. Do NOT offer glucosamine or chondroitin. Do NOT offer hyaluronan injections. Do NOT offer arthroscopic lavage. Topical NSAIDs are preferred first pharmacological step over oral.
② Greater Trochanteric Pain Syndrome / Gluteal Tendinopathy
Step 1Load management + education: Avoid provocative positions: crossing legs, sitting with hip >90° flexion, lying directly on the affected side (use pillow between knees). Analgesia: paracetamol 1g QDS ± short NSAID course if suitable (lowest effective dose, shortest duration; consider renal, cardiovascular and GI risk). Correct biomechanical contributors (foot pronation, hip abductor weakness)
Step 2Physiotherapy — gluteal tendon loading programme: Progressive hip abductor strengthening (clamshells, side-lying abduction, single-leg stance). Progressive loading improves pain and function for many patients and should be continued over time — avoid passive stretching of the IT band which compresses the tendon and worsens symptoms
Step 3Corticosteroid injection (selected patients): may provide short-term symptom relief but does not treat the underlying tendinopathy. Landmark- or image-guided according to local expertise and the target pathology (e.g. methylprednisolone 40 mg + 1% lidocaine). Combine with physiotherapy. No fixed lifetime number — consider previous response, diagnostic certainty, diabetes and infection risk, tendon pathology, potential local tissue effects and alternative physiotherapy/MSK options
Step 4Not improving despite load management and physiotherapy → physiotherapy referral intensification or MSK/orthopaedic review: ESWT (extracorporeal shockwave therapy) — NICE HTG248 (formerly IPG376, 2011): evidence limited, use only with special arrangements for governance, consent and audit or research. PRP injection via sports medicine. Surgical trochanteric bursectomy / tendon repair (rare)
⚠ Do NOT perform intra-articular hip injection for GTPS — the pathology is extra-articular. GTPS is primarily a clinical diagnosis; initial management is education, load modification and progressive hip abductor strengthening.
③ Polymyalgia Rheumatica (PMR)
Diagnosis
Compatible clinical syndrome (age >50, bilateral shoulder + hip girdle aching, morning stiffness >45 min) with exclusion of alternatives. ESR/CRP helpful but neither mandatory nor diagnostic; ESR >40 not required. Exclude elderly-onset RA, infection, malignancy, myopathy, hypothyroidism and drug-related myalgia. GCA: any new headache, scalp tenderness, jaw/tongue claudication, visual symptoms, constitutional symptoms or limb claudication → same-day specialist discussion (rheumatology/acute medicine per GCA pathway, not ophthalmology alone). If visual or neurological features are present, commence urgent high-dose glucocorticoid per the GCA pathway and do not wait for ophthalmology
First-line treatment
Prednisolone 15 mg OD orally — a rapid response is supportive, not diagnostic in isolation. If no response at 1 week, reconsider diagnosis. Bone protection: assess rather than prescribing automatically — age and sex, fragility-fracture history, dose and expected duration, FRAX/NOGG risk, renal function, calcium and vitamin D status, pregnancy potential. For people aged ≥50 on prednisolone ≥7.5 mg/day for ≥3 months, NOGG recommends starting bone protection at the same time in appropriate risk groups, without waiting for DXA
Tapering schedule
Reduce to 12.5 mg after approximately 3 weeks (if symptoms controlled). Then 10 mg after a further 3 weeks, held for 4–6 weeks. Then reduce by 1 mg every 4–8 weeks. Individualise according to symptoms, inflammatory markers, relapse and toxicity. Typical duration: 18–24 months total. Relapse common — increase to last effective dose. Refer rheumatology for relapses or steroid-sparing need (methotrexate, tocilizumab)
Monitoring
ESR/CRP monthly initially. HbA1c + BP + weight (steroid side effects). Repeat DXA guided by fracture risk and treatment decisions (NOGG/local guidance) — not routinely annual. Adrenal insufficiency risk if abrupt stop — never stop suddenly
④ Inflammatory Arthritis — New Presentation
Acute management
NSAID while awaiting rheumatology only after considering age, renal function, hypertension, cardiovascular disease, ulcer risk, anticoagulants and pregnancy — lowest effective dose, shortest duration, PPI gastroprotection where indicated, per local formulary. Do not initiate DMARD without specialist confirmation. Do not routinely start bridging prednisolone — discuss with rheumatology first
Axial SpA / AS
Affects men and women; HLA-B27 may be negative and CRP may be normal — do not diagnose on HLA-B27 alone. Refer per NICE NG65: chronic back pain starting before age 45 plus at least four additional features; if exactly three are present, HLA-B27 testing may help decide referral. NSAIDs improve symptoms. MRI uses an inflammatory back-pain protocol and is usually arranged through the specialist pathway. Physiotherapy essential — daily extension exercises
Refer urgently
Suspected persistent synovitis → urgent rheumatology referral (NICE NG100), particularly if more than one joint, small joints of hands or feet, or delay of 3 months or more. Do not delay referral for RF, anti-CCP, CRP or ESR results. Early DMARD (methotrexate ± hydroxychloroquine for RA) reduces irreversible joint damage
Next steps: see Osteoarthritis · Greater trochanteric pain syndrome · Polymyalgia rheumatica · Osteoporosis · Axial spondyloarthritis